Cargando…

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

In a large number of cancer types, treatment selection depends on the presence of specific tumor biomarkers. Due to the dynamic nature of cancer, very often these predictive biomarkers are not uniformly present in all cancer cells. Tumor heterogeneity represents indeed one of the main causes of ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Russano, Marco, Napolitano, Andrea, Ribelli, Giulia, Iuliani, Michele, Simonetti, Sonia, Citarella, Fabrizio, Pantano, Francesco, Dell’Aquila, Emanuela, Anesi, Cecilia, Silvestris, Nicola, Argentiero, Antonella, Solimando, Antonio, Vincenzi, Bruno, Tonini, Giuseppe, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254767/
https://www.ncbi.nlm.nih.gov/pubmed/32460897
http://dx.doi.org/10.1186/s13046-020-01601-2
Descripción
Sumario:In a large number of cancer types, treatment selection depends on the presence of specific tumor biomarkers. Due to the dynamic nature of cancer, very often these predictive biomarkers are not uniformly present in all cancer cells. Tumor heterogeneity represents indeed one of the main causes of therapeutic failure, and its decoding remains a major ongoing challenge in the field. Liquid biopsy is the sampling and analysis of non-solid biological tissue often through rapid and non-invasive methods, which allows the assessment in real-time of the evolving landscape of cancer. Samples can be obtained from blood and most other bodily fluids. A blood-based liquid biopsy can capture circulating tumor cells and leukocytes, as well as circulating tumor-derived nucleic acids. In this review, we discuss the current and possibly future applications of blood-based liquid biopsy in oncology, its advantages and its limitations in clinical practice. We specifically focused on its role as a tool to capture tumor heterogeneity in metastatic cancer patients.